- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Subgroup Analysis Demonstrates Promising Activity With Elacestrant in ER+/HER2- Advanced or Metastatic Breast Cancer
June 4th 2023, 7:31pm
Findings from a subgroup analysis of the phase 3 EMERALD trial presented during the 2023 ASCO Annual Meeting demonstrated elacestrant elicited prolonged progression-free survival compared with standard-of-care therapy for patients with estrogen receptor-positive, HER2-negative non-detected ESR1 mutated breast cancer who experienced disease progression within 6 months of CDK4/6 inhibitor treatment plus endocrine therapy.
TIGIT, PD-1 Bispecific Rilvegostomig Shows Promise Following Prior Immunotherapy Resistance for Advanced PD-L1+ NSCLC
June 4th 2023, 6:52pm
The PD-1 and TIGIT bispecific rilvegostomig demonstrated promising early signs of tolerability and efficacy in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer following progression on at least 1 prior checkpoint inhibitor. according to initial findings from the phase 1/2 ARTEMIDE-01 study.
Talazoparib/Enzalutamide Combo Significantly Improves rPFS in HRR Gene–Altered mCRPC
June 4th 2023, 6:13pm
The combination of talazoparib and enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression-free survival when used as a first-line therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
BRCA Mutations Associated with Worse Survival in HRR-deficient mCRPC
June 4th 2023, 5:27pm
Patients with homologous recombination repair–deficient mutations and metastatic castration-resistant prostate cancer who also harbored BRCA mutations experienced poorer survival outcomes vs patients without BRCA mutations and those with non-BRCA HRR mutations, according to an analysis from the CAPTURE trial.
Trastuzumab Deruxtecan Elicits Promising Antitumor Activity in HER2+ mCRC
June 4th 2023, 5:16pm
The 5.4-mg/kg dose of trastuzumab deruxtecan elicited numerically higher activity in patients with HER2-positive, metastatic colorectal cancer compared with the 6.4-mg/kg dose.
PRO Outcomes With Dostarlimab/Chemo Similar to Chemo Alone in 3-Year Follow-Up of Patients With Endometrial Cancer
June 4th 2023, 4:37pm
Dostarlimab maintained the health-related quality of life in patients with primary advanced or recurrent endometrial cancer.
GC012F Remains Safe, Generates Durable Responses in Relapsed/Refractory Myeloma
June 4th 2023, 3:03pm
The BCMA- and CD19-targeted CAR T-cell therapy GC012F continued to demonstrate a favorable safety profile with no new safety signals, and it elicited deep and durable responses in patients with relapsed/refractory multiple myeloma.
Vorasidenib Is Potential First Targeted Therapy for Low-Grade Glioma
June 4th 2023, 1:17pm
Treatment with the IDH1/2 inhibitor vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma, according to findings from the phase 3, double-blind INDIGO trial.
Adjuvant Osimertinib Provides OS Benefit in EGFR+ Stage IB-IIIA NSCLC
June 4th 2023, 12:00pm
Treatment with adjuvant osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo in patients with resected, EGFR-mutated, stage IB to IIIA non–small cell lung cancer.
Preoperative FOLFOX Is Noninferior to Preoperative Chemoradiation in Locally Advanced Rectal Cancer
June 4th 2023, 12:00pm
Neoadjuvant treatment with fluorouracil, leucovorin, and oxaliplatin proved to be as effective as pelvic chemoradiation with fewer adverse effects in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery.
Nivolumab With AVD Confers PFS Benefit Vs Brentuximab Vedotin Plus AVD in Advanced-stage Hodgkin Lymphoma
June 4th 2023, 12:00pm
Nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (AVD) resulted in prolonged progression-free survival (PFS) compared with brentuximab vedotin plus AVD in patients with advanced-stage classical Hodgkin lymphoma.
Mirvetuximab Soravtansine Positioned as New Standard in Frα+ Platinum-Resistant Ovarian Cancer
June 4th 2023, 12:00pm
Mirvetuximab soravtansine-gynx demonstrated a 35% reduction in the risk of disease progression or death compared with investigator’s choice of chemotherapy in patients with folate receptor alpha-high, platinum-resistant ovarian cancer.
Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy
June 4th 2023, 2:15am
Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.
Looking at the Latest Data in Lung Cancer at ASCO 2023: Dr Naidoo
June 4th 2023, 1:00am
OncLive News Network: On Location at ASCO 2023
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
BI 764532 Shows Early Efficacy, Manageable Tolerability in DLL3+ SCLC and Neuroendocrine Carcinoma
June 4th 2023, 12:39am
When administered at doses of 90 μg/kg or higher, the novel DLL3-targeting T-cell engager, BI 764532, was found to have an acceptable toxicity profile and to elicit encouraging responses in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.
Talquetamab Plus Daratumumab Produces Potent Responses in R/R Multiple Myeloma
June 4th 2023, 12:39am
Talquetamab plus daratumumab displayed high response rates regardless of 0.4 mg/kg or 0.8 mg/kg dosing in combination with daratumumab in patients with heavily pretreated relapsed/refractory multiple myeloma, irrespective of prior treatment with CD38-directed therapy and T-cell redirection therapy.
Dostarlimab Plus Chemo Leads to PFS Improvement in dMMR/MSI-H Advanced Endometrial Cancer
June 4th 2023, 12:05am
The combination of dostarlimab with standard-of-care carboplatin and paclitaxel elicited a statistically significant and clinically meaningful improvement in progression-free survival vs carboplatin/paclitaxel plus placebo in patients with mismatch repair–deficient/microsatellite instability–high advanced or recurrent endometrial cancer.
Cabozantinib Plus Nivolumab and Ipilimumab Elicits Meaningful Activity in RCCvh
June 3rd 2023, 11:54pm
Triplet therapy with cabozantinib, nivolumab, and ipilimumab demonstrated clinical meaningful activity in patients with renal cell carcinoma with variant histologies.
Dr Roddie on Obe-cel in R/R B-ALL
June 3rd 2023, 11:45pm
Claire Roddie, MD, discusses the patient population and topline efficacy findings from the phase 1/2 FELIX trial, which is investigating the CD19-directed CAR T-cell therapy obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Dr Cohen on Teclistamab Plus Talquetamab in R/R Multiple Myeloma
June 3rd 2023, 11:40pm
Yael Cohen, MD, discusses primary efficacy findings from the phase 1/2 RedirecTT-1 trial, which is investigating the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.